Medgene Labs

Medgene Labs is a biotechnology company based in Brookings, South Dakota, specializing in developing innovative vaccine platforms and immunological products for livestock and companion animals. Their proprietary technology involves constructing targeted protein antigens derived from genetic sequences of pathogens. These antigenic proteins are then used to manufacture vaccines that stimulate an effective immune response in animals.

The company's groundbreaking approach utilizes a baculovirus vector system, which allows for the rapid and animal-free production of specific protein constructs. This method eliminates the need for live viruses or infected animal tissues during the manufacturing process, ensuring a safe and controlled environment. Medgene Labs has developed over 100 protein constructs that can be used to create vaccines against various diseases affecting swine, cattle, deer, and other species.

One of Medgene Labs' notable achievements was the development of an experimental vaccine for Covid-19 in mink, as these animals were found to be highly susceptible to the virus. The company also obtained emergency use authorization from the USDA for its Rabbit Hemorrhagic Disease Virus two (RHDV2) vaccine in September 2021, providing a much-needed domestic solution for combating this fatal disease in rabbits.

Medgene Labs' platform technology allows for rapid vaccine development, with the company capable of producing a new vaccine from a genetic sequence within an average of 12 weeks. In one instance, they achieved this remarkable feat in just 21 days. This agility positions Medgene Labs as a valuable asset in responding swiftly to emerging disease outbreaks and protecting livestock herds.

In September 2021, the USDA cleared Medgene Labs' vaccine platform for use, recognizing its potential to proactively address foreign animal diseases and provide veterinarians with a powerful tool for herd protection.